Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 67%
Sell 8%
Strong Sell 0%

Bulls say

Amgen has demonstrated significant financial growth, with sales increasing by 40% in the third quarter of 2025 compared to the same period in 2024, driven by strong performances from key products like Repatha and Tezspire. The company reported that 16 products achieved double-digit growth in the same quarter, indicating robust demand across its therapeutic portfolio. Furthermore, Amgen raised its fiscal year 2025 revenue guidance to a range of $35.8 billion to $36.6 billion, highlighting the firm's ongoing strength and commitment to innovation with increased investment in research and development projected to grow by over 20% in 2025.

Bears say

The analysis indicates that Amgen is projected to experience minimal total revenue growth of approximately 1% in 2026 compared to 2025, primarily due to significant anticipated sales declines of around 28% for Prolia and 39% for Xgeva. While there is potential in emerging products and the pipeline, specifically MariTide and olpasiran, there is insufficient visibility regarding their capacity to counterbalance the erosion from the base business. Additionally, the company is facing structural challenges related to the impending loss of exclusivity for key product franchises, which further contributes to a negative outlook for the stock.

Amgen (AMGN) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 67% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 12 analysts, Amgen (AMGN) has a Hold consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $316.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $316.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.